UNSPSC 51111632: Diflomotecan

This classification denotes a camptothecin analogue with the molecular formula C21H16F2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QKT1LC4J1P, chemically known as 3h,15h-oxepino(3,4:6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-, (5r)- but generally known as diflomotecan, which bears US NIH Compound Identifier 219023. The term DIFLOMOTECAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46).

Most nations schedule diflomotecan under HS 29399900 and SITC 54149. As of Q4 2014, DIFLOMOTECAN remains the US FDA Preferred Term for this commodity. Diflomotecan bears US NLM identifiers UMLS ID C1541796 and NCI Concept Code C90824. SMILES: CC[C@]1(CC(=O)OCC2=C1C=C3C4=C(CN3C2=O)C=C5C=C(C(=CC5=N4)F)F)O.

UNSPSC 51111632 Diflomotecan (Commodity) covers pharmaceutical products and therapeutic agents procured by state health agencies to support pharmacy benefit programs and direct-to-manufacturer prescription initiatives. The code captures what state and local governments are actually buying: access to specific pharmaceutical therapeutics through alternative procurement channels designed to bypass traditional pharmacy benefit managers and group purchasing organizations, with an emphasis on direct contracting, negotiated net pricing, and outcomes-based payment models. State health and human services agencies are the primary issuing bodies under this code, pursuing procurement mechanisms that integrate pharmaceutical sourcing into broader state employee health plan administration and Medicaid-adjacent programs.

The Texas Health and Human Services Commission posted Request for Information HHS0017013 in April 2026, soliciting vendor capabilities for implementing direct-to-manufacturer prescription programs that would serve self-insured employee group health plans and state agencies outside existing PBM and GPO arrangements. This RFI represents preliminary market intelligence gathering rather than a formal competitive solicitation; the state indicated no award value, budget range, or binding timeline at that stage, with the stated intent to use vendor responses to develop detailed procurement specifications and formal RFP documentation for subsequent phases. Geographic activity under the code appears concentrated in states with large public employee health plans and active pharmacy benefit redesign initiatives, with Texas representing a documented recent entry point for direct-to-manufacturer contracting models at scale.